<DOC>
	<DOCNO>NCT00387127</DOCNO>
	<brief_summary>This phase II study compare effect lapatinib versus placebo administer concurrently cisplatin radiotherapy follow 1 year monotherapy lapatinib placebo . The study design evaluate compare two treatment group respect complete response rate 6 month follow chemoradiation completion .</brief_summary>
	<brief_title>Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : Willing able sign write informed consent ; Histologically confirm diagnosis SCCHN one follow site : oral cavity , oropharynx , hypopharynx larynx ; Multiple primary tumour : Have histologically prove ; Have anatomically distant surround normal tissue ; Exclude distant metastasis . Prior enrolment subject must ErbB1 overexpression determine immunohistochemistry ( IHC ) 3+ assessed central laboratory ; Subjects stage III IVA/IVB disease , receive cisplatin chemotherapy radiation therapy primary treatment ( total dose 65 70 Gy ) ; Subjects Tis , T1 T2 disease regardless N stage , exclude . Subjects distant metastasis , ie Stage IVC , exclude . Willing able tumour biopsy take screening ; For patient prior tumour biopsy , adequate archive specimen must available . Male female ≥18 year age ; Criteria female subject female partner male subject : Nonchildbearing potential ( i.e. , woman function ovary GM2005/00448/00 CONFIDENTIAL EGF105884 22 current document tubal ligation hysterectomy , woman postmenopausal ) ; Childbearing potential ( i.e. , woman function ovary document impairment oviductal uterine function would cause sterility . ) This category include woman oligomenorrhoea ( severe ) , woman perimenopausal , young woman begin menstruate . These subject must negative serum pregnancy test screen agree one following : Complete abstinence intercourse 2 week prior administration first dose study medication 28 day final dose study medication ; Consistent correct use one follow acceptable method birth control : male partner sterile prior female subject 's entry study sole sexual partner female subject ; implant levonorgestrel ; injectable progestogen ; intrauterine device ( IUD ) document failure rate le 1 % per year ; oral contraceptive ( either combine progestogen ) ; barrier method , include diaphragm condom spermicide . ECOG performance status 0 , 1 2 ; Subjects must adequate haematological , renal hepatic function ; Calculated creatinine clearance ≥50 ml/min determine modify method Cockcroft Gault EDTA method . Absolute neutrophil count ≥1,500/μl , platelets ≥100,000/μl . Haemoglobin ≥9gm/dL ( 5mmol/L ) . Aspartate ( AST ) alanine transaminase ( ALT ) less 4 time upper limit normal range ( ULN ) . Total bilirubin ≤2.0 mg/dL . Left ventricular ejection fraction ( LVEF ) within institutional normal range measure echocardiogram ( ECHO ) Multigated Acquisition ( MUGA ) scan ; Able swallow tablet whole swallow suspension tablet dissolve water study inclusion ; The use time feed tube optional . If necessary , suspension may administer via percutaneous endoscopic gastrostomy ( PEG ) , percutaneous jejunostomy tube ( J Tube ) , nasogastric tube ( NG Dobhoff type tube ) . Life expectancy least 6 month best judgment investigator . Exclusion criterion : Nasopharyngeal , paranasal sinus nasal cavity tumour ; Any prior current treatment invasive head neck cancer kind . This include limit : prior tyrosine kinase inhibitor , prior neoadjuvant therapy , prior surgical resection , use investigational agent ; Concurrent use CYP3A4 inducer inhibitor . A standard 3day course dexamethasone prevention cisplatininduced nausea vomiting permit ; Subjects know history uncontrolled symptomatic angina , arrhythmia , congestive heart failure ; History another malignancy within last 5 year , exception completely resect basal squamous cell skin cancer , successfully treat insitu carcinoma . History noninvasive lesion insitu carcinoma , include head neck region successfully treat surgery , photodynamics laser , permit ; Peripheral neuropathy ≥ grade 2 ; Pregnant lactating female ( female subject childbearing potential undertake pregnancy test screen study completion/withdrawal visit ) ; Malabsorption syndrome , disease significantly affect GI function , could affect absorption lapatinib ; History allergic reaction appropriate antiemetic ( e.g . 5HT3 antagonist ) administer platinum chemotherapy ; The investigator considers subject unfit study result medical interview , physical examination , screen investigation ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Neck Cancer</keyword>
	<keyword>Locally advanced head neck cancer</keyword>
	<keyword>locally advanced</keyword>
	<keyword>Head Neck cancer</keyword>
	<keyword>lapatinib</keyword>
	<keyword>EGFR/ErbB2 inhibitor</keyword>
	<keyword>Head Cancer</keyword>
</DOC>